FGF13 enhances resistance to platinum drugs by regulating hCTR1 and ATP7A via a microtubule‐stabilizing effect

Platinum‐based regimens are the most widely used chemotherapy regimens, but cancer cells often develop resistance, which impedes therapy outcome for patients. Previous studies have shown that fibroblast growth factor 13 (FGF13) is associated with resistance to platinum drugs in HeLa cells. However, the mechanism and universality of this effect have not been clarified. Here, we found that FGF13 was associated with poor platinum‐based chemotherapy outcomes in a variety of cancers, such as lung, endometrial, and cervical cancers, through bioinformatics analysis. We then found that FGF13 simultaneously regulates the expression and distribution of hCTR1 and ATP7A in cancer cells, causes reduced platinum influx, and promotes platinum sequestration and efflux upon cisplatin exposure. We subsequently observed that FGF13‐mediated platinum resistance requires the microtubule‐stabilizing effect of FGF13. Only overexpression of FGF13 with the ‐SMIYRQQQ‐ tubulin‐binding domain could induce the platinum resistance effect. This phenomenon was also observed in SK‐MES‐1 cells, KLE cells, and 5637 cells. Our research reveals the mechanism of FGF13‐induced platinum drug resistance and suggests that FGF13 can be a sensibilization target and prognostic biomarker for chemotherapy.

[1]  B. Kobal,et al.  The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Brian Craft,et al.  Visualizing and interpreting cancer genomics data via the Xena platform , 2020, Nature Biotechnology.

[3]  A. Mutsaers,et al.  Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy. , 2020, Veterinary and comparative oncology.

[4]  Robin L. Anderson,et al.  FGF13 promotes metastasis of triple‐negative breast cancer , 2020, International journal of cancer.

[5]  A. Magistrato,et al.  Copper trafficking in eukaryotic systems: current knowledge from experimental and computational efforts , 2019, Current opinion in structural biology.

[6]  D. Cohen,et al.  Knockout of the X‐linked Fgf13 in the hypothalamic paraventricular nucleus impairs sympathetic output to brown fat and causes obesity , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  W. Li,et al.  MiR-10b suppresses the growth and metastasis of colorectal cancer cell by targeting FGF13. , 2019, European review for medical and pharmacological sciences.

[8]  A. Jazaeri,et al.  Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy , 2018, Front. Immunol..

[9]  M. Kuo,et al.  Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis , 2018, International journal of molecular sciences.

[10]  Jiye Yin,et al.  Copper efflux transporters ATP7A and ATP7B: Novel biomarkers for platinum drug resistance and targets for therapy , 2018, IUBMB life.

[11]  Y. Matsumoto,et al.  Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion , 2018, Oncogene.

[12]  Ying Sun,et al.  Decreased expression of fibroblast growth factor 13 in early-onset preeclampsia is associated with the increased trophoblast permeability. , 2018, Placenta.

[13]  Ling Xie,et al.  Lentivirus Mediating FGF13 Enhances Axon Regeneration after Spinal Cord Injury by Stabilizing Microtubule and Improving Mitochondrial Function. , 2017, Journal of neurotrauma.

[14]  A. Akhmanova,et al.  Microtubule-Organizing Centers. , 2017, Annual review of cell and developmental biology.

[15]  L. Mao,et al.  Inducible Fgf13 ablation enhances caveolae-mediated cardioprotection during cardiac pressure overload , 2017, Proceedings of the National Academy of Sciences.

[16]  T. Thompson,et al.  Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. , 2017, Current medicinal chemistry.

[17]  Mirjam N Trame,et al.  Development and validation of a LC-MS/MS assay for quantification of cisplatin in rat plasma and urine. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[18]  Liu Yang,et al.  FGF13 Selectively Regulates Heat Nociception by Interacting with Nav1.7 , 2017, Neuron.

[19]  Ariana D. Sanchez,et al.  Microtubule-organizing centers: from the centrosome to non-centrosomal sites. , 2017, Current opinion in cell biology.

[20]  Hailin Zhang,et al.  Conditional knockout of Fgf13 in murine hearts increases arrhythmia susceptibility and reveals novel ion channel modulatory roles. , 2017, Journal of molecular and cellular cardiology.

[21]  T. Redmer,et al.  The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells , 2017, Oncogenesis.

[22]  Yonit Hoffman,et al.  Regulatory module involving FGF13, miR-504, and p53 regulates ribosomal biogenesis and supports cancer cell survival , 2016, Proceedings of the National Academy of Sciences.

[23]  C. Hoogenraad,et al.  Molecular Pathway of Microtubule Organization at the Golgi Apparatus. , 2016, Developmental cell.

[24]  P. Taimen,et al.  Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy , 2016, International journal of cancer.

[25]  L. Amable.  Cisplatin resistance and opportunities for precision medicine. , 2016, Pharmacological research.

[26]  S. Dilruba,et al.  Platinum-based drugs: past, present and future , 2016, Cancer Chemotherapy and Pharmacology.

[27]  J. Lüders,et al.  The Microtubule Cytoskeleton , 2016, Springer Vienna.

[28]  Cheng Luo,et al.  Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation. , 2015, Nature chemistry.

[29]  Hongzhao Lu,et al.  FGF13 regulates proliferation and differentiation of skeletal muscle by down‐regulating Spry1 , 2015, Cell proliferation.

[30]  Lukas C. Kapitein,et al.  Building the Neuronal Microtubule Cytoskeleton , 2015, Neuron.

[31]  N. Wheate,et al.  The state-of-play and future of platinum drugs. , 2015, Endocrine-related cancer.

[32]  T. Tsou,et al.  Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. , 2015, Biochemical pharmacology.

[33]  T. Enomoto,et al.  Annexin A4‐conferred platinum resistance is mediated by the copper transporter ATP7A , 2014, International journal of cancer.

[34]  K. Polyak,et al.  Oncogene-like induction of cellular invasion from centrosome amplification , 2014, Nature.

[35]  S. Knapp,et al.  Copper is required for oncogenic BRAF signaling and tumorigenesis , 2013, Nature.

[36]  C. Hoogenraad,et al.  Microtubule minus-end stabilization by polymerization-driven CAMSAP deposition. , 2014, Developmental cell.

[37]  G. Natile,et al.  Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B. , 2014, Angewandte Chemie.

[38]  T. Okada,et al.  Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells , 2013, Scientific Reports.

[39]  M. Kuo,et al.  Overcoming platinum drug resistance with copper-lowering agents. , 2013, Anticancer research.

[40]  G. George,et al.  Copper chaperone Atox1 interacts with the metal-binding domain of Wilson's disease protein in cisplatin detoxification. , 2013, The Biochemical journal.

[41]  E. Perlas,et al.  αTAT1 is the major α-tubulin acetyltransferase in mice , 2013, Nature Communications.

[42]  Liu Yang,et al.  Roles of intracellular fibroblast growth factors in neural development and functions , 2012, Science China Life Sciences.

[43]  N. Savaraj,et al.  Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. , 2012, Cancer research.

[44]  Shuai Li,et al.  Fibroblast Growth Factor 13 Is a Microtubule-Stabilizing Protein Regulating Neuronal Polarization and Migration , 2012, Cell.

[45]  N. Savaraj,et al.  Specificity Protein 1 (Sp1) Oscillation Is Involved in Copper Homeostasis Maintenance by Regulating Human High-Affinity Copper Transporter 1 Expression , 2012, Molecular Pharmacology.

[46]  I. Bertini,et al.  Probing the interaction of cisplatin with the human copper chaperone Atox1 by solution and in-cell NMR spectroscopy. , 2011, Journal of the American Chemical Society.

[47]  N. Bursac,et al.  Fibroblast Growth Factor Homologous Factor 13 Regulates Na+ Channels and Conduction Velocity in Murine Hearts , 2011, Circulation research.

[48]  Shonagh Walker,et al.  The status of platinum anticancer drugs in the clinic and in clinical trials. , 2010, Dalton transactions.

[49]  B. Blair,et al.  The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin. , 2010, Biochemical pharmacology.

[50]  D. Hanahan,et al.  Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. , 2010, Cancer cell.

[51]  S. Howell,et al.  Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs , 2010, Molecular Pharmacology.

[52]  R. Fässler,et al.  CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin , 2009, The EMBO journal.

[53]  A. Rosenzweig,et al.  Crystal structures of cisplatin bound to a human copper chaperone. , 2009, Journal of the American Chemical Society.

[54]  Gregory I. Elliott,et al.  Enhanced Delivery of Cisplatin to Intraperitoneal Ovarian Carcinomas Mediated by the Effects of Bortezomib on the Human Copper Transporter 1 , 2009, Clinical Cancer Research.

[55]  K. Inokuchi,et al.  N‐acetyltransferase ARD1‐NAT1 regulates neuronal dendritic development , 2008, Genes to cells : devoted to molecular & cellular mechanisms.

[56]  U. Jaehde,et al.  Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells , 2008, BMC Cancer.

[57]  S. Howell,et al.  The internalization and degradation of human copper transporter 1 following cisplatin exposure. , 2006, Cancer research.

[58]  B. Sawyer,et al.  Knowledge makes the money go round : building a financial services market place , 2004 .

[59]  Shaun K Olsen,et al.  Fibroblast Growth Factor (FGF) Homologous Factors Share Structural but Not Functional Homology with FGFs* , 2003, Journal of Biological Chemistry.

[60]  J. D. De Mey,et al.  A Formiminotransferase Cyclodeaminase Isoform Is Localized to the Golgi Complex and Can Mediate Interaction of Trans-Golgi Network-derived Vesicles with Microtubules* , 1998, The Journal of Biological Chemistry.

[61]  G. Bloom,et al.  A novel 58-kDa protein associates with the Golgi apparatus and microtubules. , 1989, The Journal of biological chemistry.

[62]  R. Klausner,et al.  Role of microtubules in the distribution of the Golgi apparatus: effect of taxol and microinjected anti-alpha-tubulin antibodies. , 1983, Proceedings of the National Academy of Sciences of the United States of America.